Editorial: ADAM10 in Cancer Immunology and Autoimmunity: More Than a Simple Biochemical Scissor

Editorial: ADAM10 in Cancer Immunology and Autoimmunity: More Than a Simple Biochemical Scissor

Bibliographic Details
Main Authors:	Armando Rossello, Alexander Steinle, Alessandro Poggi, Maria R. Zocchi
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2020-07-01
Series:	Frontiers in Immunology
Subjects:	metzincin NKG2D NKG2DL CD30 Hodgkin lymphoma ADAM10 exocyte
Online Access:	https://www.frontiersin.org/article/10.3389/fimmu.2020.01483/full

Similar Items

Targeting ADAM10 in Cancer and Autoimmunity
by: Timothy M. Smith, et al.
Published: (2020-03-01)

El receptor NKG2D en la frontera de la inmunovigilancia y la carcinogénesis
by: Jorge Flavio Mendoza Rincón
Published: (2014-07-01)

NKG2D Ligand Shedding in Response to Stress: Role of ADAM10
by: Alessandra Zingoni, et al.
Published: (2020-03-01)

NKG2D Ligands–Critical Targets for Cancer Immune Escape and Therapy
by: Dominik Schmiedel, et al.
Published: (2018-09-01)

Anti-NKG2D single domain-based antibodies for the modulation of anti-tumor immune response
by: Adeline Raynaud, et al.
Published: (2021-01-01)

Mesenchymal Stromal Cells Can Regulate the Immune Response in the Tumor Microenvironment
by: Alessandro Poggi, et al.
Published: (2016-11-01)

MICAgen Mice Recapitulate the Highly Restricted but Activation-Inducible Expression of the Paradigmatic Human NKG2D Ligand MICA
by: Younghoon Kim, et al.
Published: (2020-06-01)

γδ T LYMPHOCYTES AS A FIRST LINE OF IMMUNE DEFENSE: OLD AND NEW WAYS OF ANTIGEN RECOGNITION AND IMPLICATIONS FOR CANCER IMMUNOTHERAPY.
by: Maria Raffaella eZocchi, et al.
Published: (2014-11-01)

Fusion Proteins of NKG2D/NKG2DL in Cancer Immunotherapy
by: Hui Ding, et al.
Published: (2018-01-01)

NKG2D/NKG2-Ligand Pathway Offers New Opportunities in Cancer Treatment
by: Alexandra Frazao, et al.
Published: (2019-03-01)

The NKG2D/NKG2DL Axis in the Crosstalk Between Lymphoid and Myeloid Cells in Health and Disease
by: Ana Stojanovic, et al.
Published: (2018-04-01)

Bispecific NKG2D-CD3 and NKG2D-CD16 fusion proteins for induction of NK and T cell reactivity against acute myeloid leukemia
by: Melanie Märklin, et al.
Published: (2019-05-01)

NKG2C+NKG2A− Natural Killer Cells are Associated with a Lower Viral Set Point and may Predict Disease Progression in Individuals with Primary HIV Infection
by: Meichen Ma, et al.
Published: (2017-09-01)

NKG2D Natural Killer Cell Receptor—A Short Description and Potential Clinical Applications
by: Jagoda Siemaszko, et al.
Published: (2021-06-01)

NK cell autoreactivity and autoimmune diseases
by: Alessandro ePoggi, et al.
Published: (2014-02-01)

Cutting an NKG2D Ligand Short: Cellular Processing of the Peculiar Human NKG2D Ligand ULBP4
by: Tobias Zöller, et al.
Published: (2018-03-01)

Impairment of NKG2D-Mediated Tumor Immunity by TGF-β
by: Mariya Lazarova, et al.
Published: (2019-11-01)

INHIBITION OF THE NKG2D ACTIVATING RECEPTOR EXPRESSION ON CYTOTOXIC LYMPHOCYTES BY RECOMBINANT MICA PROTEIN
by: E. V. Abakushina, et al.
Published: (2017-01-01)

Developments in Carbohydrate-Based Metzincin Inhibitors
by: Doretta Cuffaro, et al.
Published: (2020-11-01)

NKG2D Polymorphism in Melanoma Patients from Southeastern Spain
by: Lourdes Gimeno, et al.
Published: (2019-03-01)

Genetic Variants of the NKG2C/HLA-E Receptor–Ligand Axis Are Determinants of Progression-Free Survival and Therapy Outcome in Aggressive B-Cell Lymphoma
by: Bettina Wagner, et al.
Published: (2020-11-01)

A Herpesviral induction of RAE-1 NKG2D ligand expression occurs through release of HDAC mediated repression
by: Trever T Greene, et al.
Published: (2016-11-01)

Cytomegalovirus-Driven Adaption of Natural Killer Cells in NKG2Cnull Human Immunodeficiency Virus-Infected Individuals
by: Emilie M. Comeau, et al.
Published: (2019-03-01)

Small-Molecule Targets in Tumor Immunotherapy
by: Hui-Fang Zhu, et al.
Published: (2018-07-01)

Bispecific NKG2D-CD3 and NKG2D-CD16 Fusion Proteins as Novel Treatment Option in Advanced Soft Tissue Sarcomas
by: Ilona Hagelstein, et al.
Published: (2021-04-01)

Chronic NKG2D Engagement In Vivo Differentially Impacts NK Cell Responsiveness by Activating NK Receptors
by: Christine Koch, et al.
Published: (2017-11-01)

ADAM and ADAMTS Proteases in Hepatic Disorders
by: Dirk Schmidt-Arras, et al.
Published: (2019-02-01)

Effects of Chronic Low-Dose Internal Radiation on Immune-Stimulatory Responses in Mice
by: Abrar Ul Haq Khan, et al.
Published: (2021-07-01)

Downregulation of MCT4 for lactate exchange promotes the cytotoxicity of NK cells in breast carcinoma
by: Yaping Long, et al.
Published: (2018-09-01)

NKG2D and Its Ligands: “One for All, All for One”
by: Alessandra Zingoni, et al.
Published: (2018-03-01)

Targeting the NKG2D/NKG2D-L axis in acute myeloid leukemia
by: Zhenhui Wu, et al.
Published: (2021-05-01)

Peningkatan Ekspresi Gen <i>NKG2D</I> Sel-sel NK oleh Brokoli untuk Mencegah Kanker
by: Diana Krisanti Jasaputra, et al.
Published: (2017-08-01)

In vitro Natural Killer cell immunotherapy for medulloblastoma
by: Lucia eFernandez, et al.
Published: (2013-04-01)

Convergent Evolution by Cancer and Viruses in Evading the NKG2D Immune Response
by: Richard Baugh, et al.
Published: (2020-12-01)

Manipulation of NKG2D ligands by cytomegaloviruses: impact on innate and adaptive immune response
by: Stipan eJonjic
Published: (2011-12-01)

The PI3K/Akt/GSK-3β/ROS/eIF2B pathway promotes breast cancer growth and metastasis via suppression of NK cell cytotoxicity and tumor cell susceptibility
by: Fengjiao Jin, et al.
Published: (2019-03-01)

NKG2A/CD94 is a New Immune Receptor for HLA-G and Distinguishes Amino Acid Differences in the HLA-G Heavy Chain
by: Gia-Gia T. Hò, et al.
Published: (2020-06-01)

Natural Killer Cell Responses during Human γ-Herpesvirus Infections
by: Christian Münz
Published: (2021-06-01)

Novel cellular immunotherapy using NKG2D CAR-T for the treatment of cervical cancer
by: Yan Zhang, et al.
Published: (2020-11-01)

Soluble NKG2D ligands in the ovarian cancer microenvironment are associated with an adverse clinical outcome and decreased memory effector T cells independent of NKG2D downregulation
by: Maulik Vyas, et al.
Published: (2017-09-01)